

Please add new claims 16-30 as follows:

Sub C1  
--16. A glycoprotein which specifically binds to urease of *Helicobacter pylori*,  
which glycoprotein is obtained by isolation and purification from a glycoprotein-containing  
substance using a method which utilizes specific adsorption to *Helicobacter pylori* urease.


17. The glycoprotein according to Claim 16, wherein the method which utilizes  
specific adsorption to *Helicobacter pylori* urease is affinity chromatography using a column  
on which the urease is immobilized.

18. The glycoprotein according to Claim 17, wherein the urease of *Helicobacter*  
*pylori* which is immobilized on the column is recombinant urease.

19. The glycoprotein according to Claim 16, wherein the  
glycoprotein-containing substance is a fraction containing glycoprotein obtained from whey  
of bovine milk.

20. The glycoprotein according to Claim 19, wherein the  
glycoprotein-containing substance is high molecular weight whey protein concentrate  
obtained from whey of bovine milk.

21. The glycoprotein according to Claim 16, wherein the glycoprotein-containing substance is high molecular weight albumen protein concentrate obtained from the albumen of chicken eggs.

 22. An inhibitor of *Helicobacter pylori* colonization, comprising as an active ingredient the glycoprotein according to Claim 16.

23. A pharmaceutical composition for preventing or treating a gastrointestinal disease caused by or associated with *Helicobacter pylori* in mammals including humans, comprising the glycoprotein according to Claim 16.

---

24. A food which prevents or treats a gastrointestinal disease caused by or associated with *Helicobacter pylori* in mammals including humans when consumed in an effective amount, comprising the glycoprotein according to Claim 16.

25. An inhibitor composition of *Helicobacter pylori* colonization, comprising the glycoprotein according to Claim 16 and an inhibitor of gastric acid secretion.

26. A pharmaceutical composition for preventing or treating a gastrointestinal disease caused by or associated with *Helicobacter pylori* in mammals including humans,

comprising the glycoprotein according to Claim 16 and an inhibitor of gastric acid secretion.

27. A process for preparing a glycoprotein which specifically binds to urease of *Helicobacter pylori*, comprising isolating or purifying said glycoprotein from a glycoprotein-comprising substance by using a method which utilizes specific adsorption to *Helicobacter pylori* urease.

28. The process according to claim 27, wherein the method which utilizes specific adsorption to *Helicobacter pylori* urease is affinity chromatography using a column on which the urease is immobilized.

29. A process for preparing an inhibitor of *Helicobacter pylori* colonization, comprising isolating or purifying a glycoprotein which specifically binds to urease of *Helicobacter pylori* from a glycoprotein-containing substance by using a method which utilizes specific adsorption to *Helicobacter pylori* urease.

30. The process according to claim 29, wherein the method which utilizes specific adsorption to *Helicobacter pylori* urease is affinity chromatography using a column on which the urease is immobilized.--